| Isis Miller, MD | |
|
300 Lackawanna Ave Ste 200, Scranton, PA 18503-2001 | |
| (570) 342-7864 | |
| Not Available |
| Full Name | Isis Miller |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 300 Lackawanna Ave Ste 200, Scranton, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699733816 | NPI | - | NPPES |
| 1013095000001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD426419 (Pennsylvania) | Secondary |
| 207Q00000X | Family Medicine | MD426419 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Allied Services Hospice | Clarks summit, PA | Hospice |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pennsylvania Hm Associates, Pc | 0547404337 | 73 |
| Lehigh Valley Physician Group | 3072425123 | 1763 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Entity Name | Family Care Centers Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669563037 PECOS PAC ID: 5395649347 Enrollment ID: O20031121000497 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Entity Name | Schuylkill Health System Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588603567 PECOS PAC ID: 0840285532 Enrollment ID: O20040420001197 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Entity Name | Advanced Inpatient Medicine Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871725366 PECOS PAC ID: 6406995778 Enrollment ID: O20091125000458 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Entity Name | Pennsylvania Hm Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841637865 PECOS PAC ID: 0547404337 Enrollment ID: O20130917000686 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Entity Name | Advanced Inpatient Medicine Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396168589 PECOS PAC ID: 8921230749 Enrollment ID: O20140410000089 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Entity Name | Advanced Inpatient Medicine Transitional Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609247030 PECOS PAC ID: 2365742079 Enrollment ID: O20151202002396 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Entity Name | Gslpg, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366006702 PECOS PAC ID: 7810226875 Enrollment ID: O20190917001763 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Isis Miller, MD 1139 Church Rd, Dallas, PA 18612-3158 Ph: () - | Isis Miller, MD 300 Lackawanna Ave Ste 200, Scranton, PA 18503-2001 Ph: (570) 342-7864 |
News Archive
In the largest ever assessment of substance use among people with severe psychiatric illness, researchers at Washington University School of Medicine in St. Louis and the University of Southern California have found that rates of smoking, drinking and drug use are significantly higher among those who have psychotic disorders than among those in the general population.
The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
A paper receiving advance online release in Nature Medicine describes a strategy for meeting one of today's most significant challenges in genomic medicine - determining whether a specific DNA variant in the non-protein-coding genome is the actual disease-causing variant of an associated disease risk.
› Verified 6 days ago
Haleigh Jo Hughes, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 Lackawanna Ave, Scranton, PA 18503 Phone: 570-961-3823 | |
Barry I Eisenberg, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 743 Jefferson Ave, Ste 104, Scranton, PA 18510 Phone: 570-346-4621 Fax: 570-346-5109 | |
Dr. Anthony Nicholas Lafalce, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 800 Linden St, Leahy Clinic For The Uninsured University Of Scranton, Scranton, PA 18510 Phone: 570-941-6112 Fax: 570-941-6165 | |
Dr. Michael J Turock, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 397 N 9th Ave, Scranton, PA 18504 Phone: 570-344-8619 Fax: 570-344-3230 | |
Stephanie Anne Boyarsky, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1789 N Keyser Ave, Scranton, PA 18508 Phone: 570-969-1904 Fax: 570-207-5314 | |
Dr. Daniel Joseph Kazmierski, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1789 N Keyser Ave, Scranton, PA 18508 Phone: 570-969-1904 Fax: 570-207-5314 | |
Dr. Gurkaramjit Singh Khaira, MBBS Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1800 Mulberry St, Scranton, PA 18510 Phone: 570-703-7351 Fax: 570-703-7801 |